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ABSTRACT
Purpose: To describe the clinical features of electric powered indoor/outdoor wheelchair (EPIOC)
users with rare diseases (RD) impacting on EPIOC provision and seating. Method: Retrospective
review by a consultant in rehabilitation medicine of electronic and case note records of EPIOC
recipients with RDs attending a specialist wheelchair service between June 2007 and September
2008. Data were systematically extracted, entered into a database and analysed under three
themes; demographic, diagnostic/clinical (including comorbidity and associated clinical features
(ACFs) of the illness/disability) and wheelchair factors. Results: Fifty-four (27 male) EPIOC users,
mean age 37.3 (SD 18.6, range 11–70) with RDs were identified and reviewed a mean of 64 (range
0–131) months after receiving their wheelchair. Diagnoses included 27 types of RDs including
Friedreich’s ataxia, motor neurone disease, osteogenesis imperfecta, arthrogryposis, cerebellar
syndromes and others. Nineteen users had between them 36 comorbidities and 30 users had 44
ACFs likely to influence the prescription. Tilt-in-space was provided to 34 (63%) users and
specialised seating to 17 (31%). Four users had between them complex control or interfacing
issues. Conclusions: The complex and diverse clinical problems of those with RDs present unique
challenges to the multiprofessional wheelchair team to maintain successful independent mobility
and community living.
 IMPLICATIONS FOR REHABILITATION
 Powered mobility is a major therapeutic tool for those with rare diseases enhancing
independence, participation, reducing pain and other clinical features.
 The challenge for rehabilitation professionals is reconciling the physical disabilities with the
individual’s need for function and participation whilst allowing for disease progression and/or
growth.
 Powered wheelchair users with rare diseases with a (kypho) scoliosis require a wheelchair
system that balances spine stability and movement to maximise residual upper limb and trunk
function.
 The role of specialised seating needs careful consideration in supporting joint derangements
and preventing complications such as pressure sores.
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Introduction
Rare diseases (RD) are conditions affecting less than five
in 10 000 of the general population,[1] or a prevalence of
fewer than 200 000 affected individuals in the United
States.[2] There are nearly 7000 rare diseases [3] with
birth prevalence ranging from 450.0 per 100 000 to
one recorded case worldwide.[4] Often RDs have no
treatment, or ineffective treatment and are known to
be very complex.[3] Many are life-threatening or
chronically debilitating diseases, often of genetic
origin.[1]
Genetics has greatly enhanced our understanding of
the cause and nature of many RDs. However, the
strategic documents relating to the management of
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RDs lack any reference to rehabilitation strategies that
could ameliorate some of the disabling consequences of
RDs,[5–11] and these reports make no reference to the
functional impact on individuals with these disorders
experiencing progressive disabilities. Furthermore, there
is no reference to the inclusion of wheelchair provision
as a means to promote participation and improve quality
of life (QOL).
Those with RDs progressing to severe mobility
impairments do not comprise a homogeneous group.
Generally, they fall into three groups comprising meta-
bolic dysfunction, for example, Morquio’s disease,
neuromuscular/neurological conditions, for example,
Dejerine–Sottas disease and connective tissue/bone
disorders, for example, osteogenesis imperfecta. Some
features of these conditions present rehabilitation pro-
fessionals with unusual challenges, including multiple
fractures, multiple contractures or skeletal malforma-
tions, dwarfism and skin affectations in addition to the
more commonly recognised issues of scoliosis and
problematic pain. The majority of those with metabolic
dysfunction and connective tissue/bone disorders do
not experience cognitive deterioration as part of the
disease progression but those with neuromuscular/
neurological conditions may develop cognitive prob-
lems, for example, motor neurone disease (MND) [12]
and progressive supranuclear palsy (PSP) [13] that may
influence ability to drive EPIOCs.
Some RDs with larger numbers do have rehabilitation
pathways and recognised mobility disability requiring
wheelchair provision, for example MND [14,15] and
Friedreich ataxia.[16] For less commonly seen RDs, case
reports can provide some knowledge about wheelchair
prescription.[17] Patient experience reports [18] and
patient surveys [19] may be helpful, while disease
registers may give insights into wheelchair use.[20] The
therapeutic uses of powered wheelchairs, as reported for
those with multiple sclerosis [21] have not been
reported in RDs to our knowledge.
In the United Kingdom, the National Health Service
(NHS) provides funded electric powered indoor/outdoor
wheelchairs (EPIOCs) to people with severe and complex
disabilities who fulfilled strict criteria.[22] Those eligible
are unable to walk around their home unaided, self-
propel and are able to utilise the chair independently.
Scooters are not provided by the NHS. Users may choose
to take the value of the prescribed EPIOC in vouchers
and purchase a chair privately.[22,23]
The consideration of wheeled and/or powered mobil-
ity can provide substantial improvements to QOL.[24]
The literature on wheelchair use in RDs appears negative
in nature – in that a condition had deteriorated such that
a wheelchair was needed for mobility.[25–29] The UK
rare disease strategy makes no reference to mobility
disability and the need for a full disability assessment
and rehabilitation.[7] This is surprising in view of the
proven benefits of powered mobility to the well-being
of electric powered indoor/outdoor powered wheel-
chairs (EPIOC) users (referred to as ‘users’), particularly
the psychological and functional gains experienced by
younger users [30] and the importance attributed by
service users to participation.[31]
Previous research has identified the wide range of
diagnoses, age and associated clinical features of recipi-
ents of EPIOCs. This research commented on the
complex interactions between the chair user and the
technical features of EPIOC prescription.[32] Users with
RDs presented unique challenges to service providers
and there is a paucity of evidence to inform clinical
decisions. It has been recommended that more research
is needed into management of patients with RD to
underpin the development of guidelines to improve
care.[7] Consequently, this study explores a subgroup,
diagnosed with RDs, of a larger cohort with severe
mobility disability.[32]
Similar to other groups of very severely disabled
individuals, those with RDs face issues of ageing with a
disability as well as the continuing trajectory of their
condition, which for many will be deteriorating.[33] It is
also recognised that they will experience secondary
pathologies with accelerated age-related conditions or
comorbidities.[34] Powered mobility is recognised to
improve access and autonomy of persons ageing with a
disability and it has been emphasised that understand-
ing the specific needs of individuals is required to adapt
assistive technologies in a way that is beneficial and
useable.[34] ‘Recognising the patients’ individual symp-
tomatic pattern of comorbidity’ [35] is seen to be critical
for analyses that extend beyond the diagnostic label to
‘improve health status’.[35]
Therefore, the aim of this cross-sectional study is to
describe those demographic and clinical features of
people with RDs that impact on EPIOC provision and
seating needs and to explore the complexities of
comorbidities, features of RDs and conditions secondary
to disability that impact on powered wheelchair provi-
sion and clinical management. Because many RDs are
present from birth, a further aim was to determine
whether age influenced the prescription of seating and
chair features.
Methods
This is a cross-sectional study of a clinic population with
retrospective review of electronic and case note records.
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The setting
The Specialist Wheelchair Service at Stanmore was set up
in 1997 [22] to provide a regional service for around 3.1
million people from both rural and inner city areas.
Provision was limited to those who were unable to walk
safely around their home, unable to self-propel and were
judged safe to use their chairs in public places
irrespective of age, diagnosis or time using a wheelchair
(if any). The full eligibility criteria have been
published.[22]
Provision involved:
 Completion of a screening questionnaire.
 Occupational therapy assessment for the suitability of
the home environment and the likelihood that the
eligibility criteria would be fulfilled.
 Children were assessed by their paediatric therapist
to provide details of current management and an
evaluation of cognitive, emotional, visuospatial and
physical development relating to their suitability for
EPIOC driving.
 Assessment at the multiprofessional (as recom-
mended [36]) specialist regional service including
eye and physical examination to define any problems
with seating or controlling a powered wheelchair,
concluding with a driving assessment to ensure
satisfactory control of the wheelchair and safety for
the users and others.
 A rehabilitation engineer delivered the wheelchair
and explained its use, checked seating and that
driving appeared satisfactory.
Participants
Potential participants lived in the community and were
referred from their local wheelchair service to the
specialist regional service which decided provision of
an EPIOC based on clinical grounds. Inclusion criteria for
this study were all individuals, who had been prescribed
an EPIOC, were currently using their chair and had a
diagnosis of a RD defined as a condition affecting less
than five in 10 000 of the general population,[1] of
metabolic, neurological or neuromuscular origin and
recorded as the main diagnosis for ten or fewer
individuals. Exclusions were those who did not fulfil
the eligibility criteria for NHS EPIOC use.[22]
Data collection
Data had been recorded in two main sources. Firstly, the
electronic record contained personal, demographic and
diagnostic information. EPIOC prescriptive features
included use of special seating (SS) (adaptive seating),
tilt-in-space (TIS) and complex controls. Demographic
data, diagnosis and wheelchair factors had been entered
into the electronic record by health professionals after a
multiprofessional physical assessment and examination.
Secondly, patient notes (charts) contained clinical details
relevant to the EPIOC provided.
Both records were reviewed between June 2007 and
September 2008 by a consultant physician in rehabilita-
tion medicine who was responsible for all patient care.
Data were systematically extracted and entered into a
computer database for analysis and all data anonymised.
Demographic profiles consisted of information on age
and gender at initial assessment. Clinical profiles
included: primary diagnosis, comorbidities, other clinical
features and complications relating to the disability.
Wheelchair factors included information about SS,
defined as ‘that which is needed by people who require
a wheelchair but due to instability or deformity need
additional support in order to function’.[37] Other data
included TIS, cushions and complex controls.
Methods of analysis
Data were analysed to describe proportions and
frequencies of variables relating to wheelchair features
and SS provision. Comorbidities (conditions with no
known or unlikely association with the index diagnosis),
features of the RD and features of disability were
categorised by type of description and by frequency of
occurrence. Descriptive statistics were used to analyse
demographic data (age and sex). Clinical issues were
categorised into major diagnosis contributing to the
need for a wheelchair and whether it was inherited
(autosomal dominant, recessive or X-linked).
Data were analysed using t tests for significant
differences in age between those users with SS or TIS
and without.
This study was approved by the National Research
Ethics Service.
Results
Fifty-four EPIOC users, mean age 37.3 (SD: 18.6; range:
11–70) years met the inclusion criteria. There were 27
males mean age 36 (SD: 17.7; range: 11–68) years and 27
females mean age 38.7 (SD: 19.8; range: 13–70) years.
The incidence or prevalence of their condition (where
known) are given in Table 1 and their diagnoses and
clinical features are given in Table 2.
The majority of users had neurological conditions
(n¼ 31) of which 10 had Friedreich’s ataxia (five men,
five women mean age 29.1, range 16–43, SD 11.0 years)
and six had motor neurone disease (five men, one
RARE DISEASES AND POWERED MOBILITY 1549
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woman mean age 58, range 51–63 years). A further three
had neuromuscular conditions (central core disease,
dystrophia myotonica and congenital myasthenia.
Twenty users had disorders involving connective tis-
sue and 42 users had inherited conditions, including
two sisters both with infantile systemic hyalinosis
(Table 2).
Comorbidities and additional clinical features
Sixteen users (30%) had no comorbidities or ACFs
(Table 2). Nineteen users had between them 35
comorbidities and 31 users had a total of 45 ACFs
(Table 2). Back pain was a common comorbidity (n¼ 7)
and one user had additional neck pain. Six users had
three or more comorbidities.
Hypertension was reported in five users. Scoliosis was
a frequent ACF (n¼ 8), as was problematic pain (n¼ 10),
often associated with other ACFs (Table 2). Four users
had three or more ACFs. Eight users had needed
orthopaedic surgery prior to EPIOC provision.
Wheelchair features
TIS was provided to 34 (63%) users and SS to 17 (31%)
(Table 2). Six users had individually tailored seating
systems. Carved foam seating was provided to three
(Morquio’s with cervical and spinal fusions, Friedreich’s
ataxia with a scoliosis and infantile systemic hyalinosis
with severe scoliosis and fragile skin), Caps ll to a user
with Krabbe’s disease, Matrix seating to a user with
osteogenesis imperfecta and one user with Pelizaeus–
Merzbacher disease was provided with a moulded seat
insert. All other users needing SS were provided with
appropriate standard cushions. Only three users who
were provided with SS did not have one or more ACFs.
TIS was provided to all eight users with scoliosis and SS
to six with scoliosis.
Those provided with SS were significantly younger
than those who had standard equipment (p50.004).
There was no significant difference in age between those
provided with TIS and those without.
Complex controls
Four users had between them complex controls (3),
interfacing issues (2) and were tray mounted (2). A male
aged 26 with osteogenesis imperfecta and comorbid
asthma was provided with a tray mounted non-standard
control system that needed to interface with other
equipment. He required matrix seating but not TIS. A 16-
year-old female user with infantile systemic hyalinosis
complicated by scoliosis and poor skin condition needed
extra sensitive complex controls, SS and TIS. A 23-year-
old male with familial spastic paraplegia needed a tray
mounted complex control and SS. A 20-year-old female
with Krabbe’s disease needed controls interfacing with a
communication aid, SS and TIS.
Ventilation
Two users required wheelchair structures to support
their oxygen cylinders. One was a 17-year-old male with
Morquio’s disease complicated by lumbar and cervical
spine fusions, hip and knee surgery and residual severe
pain. He was also prescribed SS and TIS. The other was a
59-year-old male with motor neurone disease who also
needed assessment for an environmental control unit.
He was also provided with TIS but did not require SS.
Discussion
The 54 EPIOC users with RDs reported in this paper are a
heterogeneous group, many with conditions rarely seen in
clinical practise. Nonetheless, they make up 10% of the
whole EPIOC cohort.[32] This is the first study of EPIOC
users with RDs that focuses on the implications for the
wheelchair components of rehabilitation. This may reflect
the emphasis placed historically on research into the
genetics and diagnosis of these RDs and the previously low
level of support for younger physically disabled individuals
in the UK.[62,63] However, these individuals with RDs
will seldom be seen in locality-based rehabilitation services.
It is important that the proposed centres for the
study of these conditions [8,9] include rehabilitation
expertise.
For those with inherited conditions, the progress of
each individual is unique depending on activity levels,
growth rate and development. The challenge for EPIOC
providers is to reconcile the physical disabilities with the
individual’s need for function and participation whilst
allowing for future disease progression and/or growth (for
children). This is particularly important for those with small
stature, for example, Morquio’s disease and for those with
extreme vulnerability, for example, osteogenesis imper-
fecta. This is illustrated by the individual with Morquio’s
disease who needed a complex prescription to accom-
modate the sequelae of his multiple orthopaedic surgery
and need for oxygen. The SS (bespoke-carved foam)
supported his joint derangements, while the TIS helped to
minimise his problematic pain. He was provided with a 6-
wheeled EPIOC providing a more stable base for a chair
needing to accommodate an oxygen cylinder. However,
for this individual, his residual abilities enabled him to
control his chair using a standard joystick.
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Comorbidity and additional clinical features
The results show that only 30% of this cohort had a
single diagnosis, the remainder presented with complex-
ities including a range of comorbidities and ACFs. It is
often difficult to determine whether clinical issues are
due to the condition itself or the physical prob-
lems caused by disability and immobility.
Therefore, while epilepsy is a noted comorbidity in
familial spastic paraplegia, it is a known ACF of
Pelizaeus–Merzbacher disease. Epilepsy is not a contra-
indication to EPIOC use providing the user is day-
time grand mal fit-free for at least one year, similar to the
implications for drivers of motor vehicles.[64]
It is thought that individuals with Friedreich’s ataxia are
predisposed to developing diabetes.[65] One user with
Friedreich’s ataxia had diabetes which was recognised as an
ACF. There may be no immediate implications for EPIOC
prescription in those with uncomplicated diabetes, although
it may eventually predispose users to pressure sores and leg
ulcers. In contrast, one user with motor neurone disease also
had diabetes complicated with a below-knee amputation
which was noted as a comorbidity. For those with severe
immobility disability, such as to require an EPIOC, dietary
advice seems critical to prevent weight gain, obesity and
minimise diabetic risk (as noted with multiple sclerosis [21]).
Pain was a common clinical finding in this group with
problematic pain affecting 10 users. Provision of a
wheelchair in individuals with Morquio’s disease has
been reported to alleviate pain and reduce fatigue,
although it is also indicated that health-related QoL is
reduced in wheelchair users.[19] It is likely that a similar
situation applies to many EPIOC users and the provision
Table 1. Diagnosis, incidence/prevalence and effects of rare diseases in 54 electric powered indoor/outdoor wheelchair users.
Condition Also called Incidence/prevalence* Effects
Achondroplasia Achondroplastic dwarfism 1:26 000–34 608 [38] Mutation of fibroblast growth factor
receptor
Arthrogryposis ARC Syndrome 1:3000 [39] Soft-tissue, joint & skeletal deformity
Ataxia telangectasia 0.4:100 000* [40] Progressive difficulty with coordinating
movements (ataxia)
Central core disease Shy–Magee syndrome 56:100 000 live births [41,42] Congenital myopathy
Cerebellar syndromes 0.3–2:100 000 for spinocere-
bellar [43]
Dysfunction of balance and movement
Congenital myasthenia Erb-Goldflam syndrome Unknown–very rare [44] Neuromuscular weakness
Dejerine–Sottas disease HMSN TYPE 111 51:1 000 000 [45] Polyneuropathy
Dystrophia epidermolysis bullosa 12–19/million births [46,47] Skin erosion and blistering
Dystrophia myotonica 10.6:100 000* [42] Progressive muscle wasting and weakness
Familial spastic paraplegia Hereditary spastic paraplegia
Stru¨mpell-Lorrain syndrome
1.5–2.7:100 000 [48] Progressive and severe lower extremity
weakness and spasticity.
Fibrodysplasia ossificans progressiva Myositis ossificans 1:2 000 000* [49] Ossification of connective tissue
Friedreich’s ataxia 0.15:100 000* [40] Dysfunction of balance, movement and
proprioception
Guillain–Barre syndrome 0.34 and 1.34/100 000 [50] Acute progressive muscle weakness
Infantile systemic hyalinosis Hyaline fibromatosis syndrome 51:1 000 000 (52 reported
cases worldwide) [51]
Hyalin deposits in tissues
Keratoderma Focal palmoplantar keratoderma Unclear Severe blisters and calluses on the feet
Krabbe’s disease Galactocerebrosidase deficiency; glo-
boid-cell leukodystrophy
1:100 000* [52] Cerebral demyelination
Leukodystrophy: undiagnosed 51:7663 births [53] Progressive demyelination resulting in
widespread motor and sensory
dysfunction
McCune–Albright syndrome Polyostotic fibrous dysplasia 1:100 000–1 000 000 people
worldwide [54]
Fibrous dysplasia of bone, progressive
scoliosis, short stature
Morquio’s disease Mucopolysaccharidosis 1:100 000 births [55] Enzyme deficiency
Motor neurone disease Amyotrophic lateral sclerosis 0.6–2.4:100 000 [56] Degeneration of motor neurones resulting
in muscle weakness and wasting
Multisystem atrophy 0.6 cases per 100.000 [57] Combination of parkinsonian, autonomic,
cerebellar or pyramidal symptoms and
signs
Osteogenesis imperfecta Brittle bone disease 1:20 000 births [58] Connective tissue
Pelizaeus–Merzbacher disease Cockayne–Pelizaeus–Merzbacher dis-
ease; PMD
51:100 000 [53] Growth of the myelin sheath
Progressive supranuclear palsy 1 per 100 000 [59] Severe parkinsonism
Sandhoff’s disease Sandhoff–Jatzkewitz–Pilz disease;
Total hexosaminidase deficiency
1:422 000 [60] Neuronal destruction in brain and spinal
cord
Spondylocostal dysplasia Jarcho–Levin syndrome; spondylocos-
tal dysostosis;
0.25/10 000 births [39] Severe malformations of the vertebral
column and ribs
Winchester syndrome Winchester disease 51:1000 000 (10 patients
reported up to 2001)* [61]
Short stature, generalised osteolysis and
progressive painful arthropathy
*Prevalence.
RARE DISEASES AND POWERED MOBILITY 1551
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of TIS is one strategy for alleviating this pain.[66,67] In
this group with RD, there is a preponderance, not seen in
other studies, of powered wheelchair users with diseases
affecting the musculoskeletal system, including the need
for orthopaedic surgery with risks of post-surgical pain,
which may be alleviated by SS and TIS. Some ACFs noted
are those that would be associated with prolonged
sitting in a wheelchair including pressure sores, oedema
and thromboembolism.
Wheelchair features
The eight users with clinically significant scoliosis present
specific challenges for EPIOC providers. An appropriate
balance must be sought between stabilising the spine
and retaining flexibility in the wheelchair system to
maximise residual upper limb and trunk function. This
was resolved by providing TIS for flexibility and pain
management to all eight users with scoliosis and SS to the
six users needing extra support. While surgery can
ameliorate the progression of a scoliosis,[68] for many a
scoliosis needs postural support by using SS to maintain
posture and thus improve function.[16] The significant
finding that those provided with SS was younger that
those without such provision is likely to reflect the need
for postural stability especially during growth.
Our largest group were those with Friedreich’s ataxia
(n¼ 10). It is recognised that, although some users with
Friedreich’s ataxia become unable to control their wheel-
chair,[18] many remain able to do so without use of non-
standard control systems or use of head or foot controls
as shown in this study. This possibly reflects the fact that
weakness is not the primary impairment for those with
Friedreich’s ataxia.[69] Problematic pain was an issue for
many Friedreich’s ataxia users and seven of the users had
TIS which would help to manage pain.[70,71]
Complex controls are needed when the user cannot
manage a standard joystick. For those with substantial
upper limb weakness and residual manual dexterity, the
use of tray-mounted controls provide support for the
weak upper limb allowing movement of the hand and
fingers to be utilised. This was the case for two users,
one with osteogenesis imperfecta and the other with
familial spastic paraplegia. Tray-mounted controls also
facilitate interfacing controls for those who need add-
itional electronic assistive technologies, as in the case of
the user with osteogenesis imperfecta. For one user
(with infantile systemic hyalinosis) with extremely
limited manual dexterity, the option of extra sensitive
controls enabled her to remain in control of her chair.
Tray-mounted joysticks may compete with space
needed (e.g. for computers).
Rehabilitation issues
This paper contributes to the care pathways and clinical
competencies that the UK Department of Health is
striving to achieve.[6] Although rehabilitation is trad-
itionally considered to be assisting recovery, rehabilita-
tion professionals should also facilitate community living
and participation for those with deteriorating conditions,
which may be very hard to live with.[18] Often this will
require assistive technologies including powered mobil-
ity being provided [14] and is best effected by a
comprehensive service delivered by a multiprofessional
team [72] including rehabilitation engineers skilled in
assistive technology (as provided for our users). Previous
research has shown that users and their families are
generally satisfied with the EPIOC service pro-
vided,[30,73] but some were concerned that they
would not be assessed for their changing needs as
they had deteriorating conditions. [74] This is particularly
important for those with RD, many of whom will
deteriorate over time.
For those with inherited RD, other family members may
have developed an identical or similar disease. This was
demonstrated by the two sisters with infantile systemic
hyalinosis who needed a high level of family support and
when provided with EPIOCs, required a larger home
which the rehabilitation team recommended.
Although it is reported that health related QoL is
reduced and carer burden increased in wheelchair users
with Morquio’s disease,[19] there is good evidence that
provision of an EPIOC improves quality of life [24] and
reduces caregiver burden, particularly as the need to
push a manual wheelchair is reduced.[74]
Although 75% of RD are in children,[75] some condi-
tions may not have progressed to severe mobility
disability until the individuals have reached adulthood.
In our cohort, two such examples are EPIOC users with
Sandhoff’s disease and Pelizaeus–Merzbacher disease
who were aged 52 and 36, respectively. What is unclear
from data we were able to obtain was information about
their rehabilitation pathway that led them to referral for
an EPIOC (noting that those in the United Kingdom could
self-refer to a wheelchair service). However, recent
European recommendations for the management of
mucopolysaccharidosis type 11 focuses on multidisciplin-
ary team support, including physiotherapy to maintain
ambulation with assistive devices if needed.[76] The lack
of any mention of assistive technology in that review is
not atypical. It reflects the lack of understanding of
powered mobility as a major therapeutic tool,[77]
enhancing mood through greater independence and
social interaction, reducing pain, assisting swallowing and
ventilation on occasions, and reducing caregiver burden.
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Study limitations
It is recognised that the ACFs of these rare diseases may
be incomplete or imprecise due to the paucity of
literature reporting long-term follow-up of these indi-
viduals.[7] However, in the future, the development of
registries for RDs will improve clinical data collection.[7]
A combination of the rarity of the disease and progres-
sion to severe mobility disability resulted in a modest
sized group for this study. Currently, there is a lack of
evidence to indicate what proportions of those with RDs
will progress to requiring an EPIOC.
Because data were extracted from records that were
designed for clinical use, only data relevant to EPIOC
prescription were recorded. The data represent the
clinical picture at a particular time, often when their
condition is deteriorating which creates specific issues for
wheelchair services.[67] This may limit generalisability to
other powered wheelchair populations, although the
majority of this RD group are likely to progress. Service
reorganisation prevented further follow-up of these users.
Our study did not include those who had purchased
wheelchairs privately or through charitable funding
(more often available for children). Users of mobility
scooters were not included.
Conclusions
These EPIOC users with rare diseases reached the
wheelchair service in their adult or teenaged years
despite having an inherited and incurable (and often
progressive) health condition. Their complex and diverse
clinical problems presented unique challenges to the
multi-professional wheelchair team to maintain success-
ful community living. Combinations of problems arising
from the RD trajectory, complications of disability and
the acquisition of comorbidities presents a complex
clinical picture that may appear daunting to rehabilita-
tion professionals. This is compounded by a lack of
research data on the rehabilitation of those with RDs.
Our research has demonstrated that a multiprofessional
rehabilitation team skilled in mobility assistive technol-
ogy can resolve these challenges by approaching
powered wheelchair provision from a therapeutic per-
spective to achieve independent mobility.
The recommended national strategies for RD [6,78,79]
need to include rehabilitation in all its complexity and the
potential of assistive technology to improve the well-
being of those with RD and their families. Early assess-
ment and regular review may help to address problems of
severe disability and clinical complications before they
have become established and require complex remedial,
rehabilitation and medical interventions.
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